A phase 1, open-label, dose-escalation, multiple dose study of the safety, tolerability, and immune response of CRS-207 in adult subjects with selected advanced solid tumors who have failed or who are not candidates for standard treatment
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2012
At a glance
- Drugs CRS 207 (Primary)
- Indications Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- 07 Feb 2012 Results were published in Clinical Cancer Research.
- 18 Apr 2011 Top-line results reported in a Aduro BioTech media release.
- 15 Jul 2010 Tolerability and preliminary analysis of long-term survival data has been reported in a Aduro Biotech media release. Further results are expected later in 2010.